Call Options

21 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 07, 2024

BUY
$3.54 - $8.35 $216,294 - $510,185
61,100 New
61,100 $448,000
Q4 2022

Feb 14, 2023

BUY
$9.86 - $23.83 $70,006 - $169,193
7,100 Added 33.97%
28,000 $282,000
Q3 2022

Nov 14, 2022

BUY
$21.04 - $36.06 $130,448 - $223,572
6,200 Added 42.18%
20,900 $468,000
Q2 2022

Aug 15, 2022

SELL
$17.78 - $42.39 $634,746 - $1.51 Million
-35,700 Reduced 70.83%
14,700 $364,000
Q1 2022

May 16, 2022

BUY
$29.67 - $60.28 $629,004 - $1.28 Million
21,200 Added 72.6%
50,400 $1.95 Million
Q4 2021

Feb 14, 2022

SELL
$47.84 - $64.34 $564,512 - $759,212
-11,800 Reduced 28.78%
29,200 $1.71 Million
Q3 2021

Nov 15, 2021

SELL
$59.27 - $95.73 $1.72 Million - $2.78 Million
-29,000 Reduced 41.43%
41,000 $2.43 Million
Q2 2021

Aug 11, 2021

SELL
$67.25 - $92.52 $2.85 Million - $3.92 Million
-42,400 Reduced 37.72%
70,000 $6.08 Million
Q1 2021

May 17, 2021

BUY
$72.16 - $117.4 $4.42 Million - $7.2 Million
61,300 Added 119.96%
112,400 $9.27 Million
Q4 2020

Feb 16, 2021

BUY
$38.09 - $100.95 $167,596 - $444,180
4,400 Added 9.42%
51,100 $4.65 Million
Q3 2020

Nov 16, 2020

SELL
$30.41 - $40.5 $790,660 - $1.05 Million
-26,000 Reduced 35.76%
46,700 $1.87 Million
Q2 2020

Aug 14, 2020

SELL
$20.21 - $35.23 $816,484 - $1.42 Million
-40,400 Reduced 35.72%
72,700 $2.49 Million
Q1 2020

May 15, 2020

SELL
$17.28 - $31.88 $825,984 - $1.52 Million
-47,800 Reduced 29.71%
113,100 $2.51 Million
Q4 2019

Feb 14, 2020

SELL
$13.39 - $20.73 $224,952 - $348,264
-16,800 Reduced 9.45%
160,900 $3.15 Million
Q3 2019

Nov 14, 2019

SELL
$15.47 - $22.5 $1.51 Million - $2.2 Million
-97,600 Reduced 35.45%
177,700 $2.76 Million
Q2 2019

Aug 14, 2019

BUY
$15.61 - $20.44 $1.19 Million - $1.56 Million
76,300 Added 38.34%
275,300 $5.59 Million
Q1 2019

May 15, 2019

BUY
$13.15 - $18.71 $717,990 - $1.02 Million
54,600 Added 37.81%
199,000 $3.5 Million
Q4 2018

Feb 14, 2019

BUY
$11.48 - $16.98 $532,672 - $787,872
46,400 Added 47.35%
144,400 $1.85 Million
Q3 2018

Nov 14, 2018

BUY
$8.75 - $16.29 $539,000 - $1 Million
61,600 Added 169.23%
98,000 $1.6 Million
Q2 2018

Aug 14, 2018

SELL
$9.16 - $13.48 $90,684 - $133,452
-9,900 Reduced 21.38%
36,400 $413,000
Q1 2018

May 15, 2018

BUY
$6.3 - $13.77 $291,690 - $637,551
46,300 New
46,300 $452,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $307M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.